FPR2 and glomerulosclerosis: By modulating the pro-inflammatory process via the lipoxin A4 LXA4-ALX/FPR2 axis, MSCs decrease the likelihood of DN progressing to glomerulosclerosis, inhibit glomerulosclerosis and pro-inflammatory cytokines, and contribute to kidney homeostasis [74].